A Pilot Study Using ctDNA Testing to Inform Standard-of-Care Treatment Decisions in People With Endometrial Cancer

Full Title

Pragmatic Pilot Study of ctDNA Informed Immune Checkpoint Inhibitor De-escalation in Advanced/Recurrent Mismatch Repair Deficient (MMR-D)/Microsatellite Instability High (MSI-H) Endometrial Cancer Using Standard of Care Treatments

Purpose

Chemotherapy plus immunotherapy with drugs called checkpoint inhibitors (ICI) is a standard treatment for some people with advanced endometrial cancer. This is particularly true for those whose tumors are called mismatch repair deficient (MMR-D) or microsatellite instability high (MSI-H). This treatment may last for 2 to 3 years, including maintenance therapy after initial treatment.

However, most cancer recurrences happen within the first year of treatment. Long-term ICI therapy can also cause lasting side effects and be expensive. Doctors are therefore interested in finding ways to identify which patients can stop maintenance therapy sooner.

Researchers want to see if circulating tumor DNA (ctDNA) testing can help decide when it might be safe to stop maintenance ICI. ctDNA is DNA released by tumor cells directly into the bloodstream. If ctDNA testing shows no signs of cancer in the blood after 1 year of treatment, you may be able to safely stop maintenance ICI. Doing so may help avoid unnecessary side effects and costs.

Who Can Join

To join this study, there are a few conditions. You must:

• Have endometrial cancer that spread or came back and is MMR-D or MSI-H.
• Be eligible for standard chemotherapy and ICI treatment.
• Be age 18 or older.

Contact

For more information about this study or to see if you can join, please call Dr. Ying Liu’s office at 646-888-4946.